AstraZeneca PLC has stopped a late-stage trial for its lung cancer drug Volrustomig. The company cited a lack of improvement in survival rates compared to existing treatments. This decision, announced on Monday, follows a recommendation from the Independent Data Monitoring Committee after reviewing trial data. This is the second setback for AstraZeneca's pipeline in just over a month. In July, the company abandoned a heart disease drug trial, which caused billions to be wiped off its market value.
Key Details
Susan Galbraith, an executive vice president at AstraZeneca, called the decision a disappointment. She said, "While we are disappointed, we will learn from this trial and are determined to continue pioneering new medicines from our industry-leading pipeline in our quest to improve outcomes for patients with lung cancer." Lung cancer is the leading cause of cancer death worldwide, making up nearly 23% of all cancer cases.
Background
Despite this setback, AstraZeneca plans to continue trials for Volrustomig in treating other cancers, such as cervical cancer and mesothelioma. The company also reported positive results for its Enhertu treatment. This treatment showed a statistically significant improvement in delaying disease progression for patients with non-small cell lung cancer. Enhertu will move to a phase three trial, which is a critical step forward given the limited treatment options for this aggressive form of cancer.
Related coverage: FTSE 100 Declines as AstraZeneca Drops Amid Oil Price Fall.
AstraZeneca's stock may see volatility as investors react to the halted trial and the mixed news from other oncology treatments. The company's focus on developing new therapies could affect its long-term growth prospects. Watch for further updates on AstraZeneca's ongoing trials and any new data releases regarding its drug pipeline.
Based on reporting by: proactiveinvestors.co.uk, standard.co.uk